Semaglutide Reduces Cardiovascular Outcomes in Non-Diabetes Patients With Established Cardiovascular Disease, Obesity
In this article, Michael Bloch, MD, and Evan Bloch discuss findings from the SELECT trial, including the use of the glucagon-like peptide 1 receptor agonist, semaglutide, to reduce the risk of major cardiovascular events in patients with cardiovascular disease and obesity without diabetes.